Cellectis (STU:ZVA) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZVA Cellectis SA STU:ZVA
59 GF Score
Price €2.76
GF Value €2.58
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Cellectis Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:ZVA
59GF Score
Cellectis SA STU:ZVA
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (STU:ZVA) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be overvalued. The current stock price of €2.76 is trading 6.9% above its estimated GF Value™ of €2.58. GuruFocus considers Cellectis to be Fairly Valued.

Key valuation signals for STU:ZVA:

  • Interest Received:
  • GF Value™: €2.58 vs. price of €2.76 (6.9% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the STU:ZVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
59GF Score

Get the complete analysis for STU:ZVA

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.76
Price
€2.58
GF Value